Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
NSAIDs vs placebo Symptomatic VTE · people with superficial thrombophlebitis of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 0.91 [0.25, 3.28] | 1 study · 211 participants | Low |
NSAIDs vs placebo Major bleeding · people with superficial thrombophlebitis of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | 1 study · 211 participants | Low |
NSAIDs vs placebo Extension or recurrence (or both) of ST · people with superficial thrombophlebitis of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 0.46 [0.27, 0.78] | 1 study · 211 participants | Low |
NSAIDs vs placebo Mortality · people with superficial thrombophlebitis of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo Minor bleeding · people with superficial thrombophlebitis of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo Adverse effects of treatment · people with superficial thrombophlebitis of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | NR | No studies |
Fondaparinux vs placebo Extension of ST Ultrasonography · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 0.08 [0.03, 0.22] | 1 study · 3002 participants | Moderate |
Fondaparinux vs placebo Recurrence of ST Ultrasonography · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 0.21 [0.08, 0.54] | 1 study · 3002 participants | Moderate |
Fondaparinux vs placebo Mortality · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 2 [0.18, 22] | 1 study · 3002 participants | Moderate |
Fondaparinux vs placebo Minor bleeding · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 1.49 [0.53, 4.17] | 1 study · 2987 participants | Moderate |
Fondaparinux vs placebo Adverse effects of treatment · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 1.13 [0.78, 1.65] | 1 study · 2987 participants | Moderate |
Prophylactic LMWH vs placebo Symptomatic VTE · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 1.22 [0.38, 3.89] | 1 study · 222 participants | Low |
Prophylactic LMWH vs placebo Major bleeding · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | 1 study · 222 participants | Low |
Intervention NR Success of prosthetic rehabilitation (preference) (1 day) · adults over the age of 50 with a unilateral transfemoral amputation Prosthetic rehabilitation for older dysvascular people following a unilateral transfemoral amputation (2018) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Intervention NR Adverse effects (1 day) · adults over the age of 50 with a unilateral transfemoral amputation Prosthetic rehabilitation for older dysvascular people following a unilateral transfemoral amputation (2018) · Cochrane | no estimate extracted | NR | No studies |
Supervised exercise therapy vs home‐based exercise therapy Maximal treadmill walking distance after 3 months · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 8 studies · 351 participants | Moderate |
Supervised exercise therapy vs walking advice Self‐reported functional impairment after 3 months (Walking Impairment Questionnaire combined) Scale: 1 to 100 (higher scores indicate better walking) · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 4 studies · 483 participants | High |
Home‐based exercise therapy vs walking advice Maximal treadmill walking distance after 3 months · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 4 studies · 137 participants | Moderate |
Home‐based exercise therapy vs walking advice Pain‐free treadmill walking distance after 3 months · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 3 studies · 107 participants | Low |
Home‐based exercise therapy vs walking advice Quality of life ‐ physical after 3 months (Short Form 36 physical component summary) Scale: 1 to 100 (higher scores indicate better quality of life) · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Home‐based exercise therapy vs walking advice Quality of life ‐ mental after 3 months (Short Form 36 mental component summary) Scale: 1 to 100 (higher scores indicate better quality of life) · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Home‐based exercise therapy vs walking advice Self‐reported functional impairment after 3 months (Walking Impairment Questionnaire combined) Scale: 1 to 100 (higher scores indicate better walking) · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 2 studies · 79 participants | Moderate |
Supervised exercise therapy vs home‐based exercise therapy Pain‐free treadmill walking distance after 3 months · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 7 studies · 322 participants | Moderate |
Supervised exercise therapy vs home‐based exercise therapy Quality of life ‐ physical after 3 months (Short Form 36 physical component summary) Scale: 1 to 100 (higher scores indicate better quality of life) · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 2 studies · 68 participants | Low |
Supervised exercise therapy vs home‐based exercise therapy Quality of life ‐ mental after 3 months (Short Form 36 mental component summary) Scale: 1 to 100 (higher scores indicate better quality of life) · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 2 studies · 68 participants | Low |
Supervised exercise therapy vs home‐based exercise therapy Self‐reported functional impairment after 3 months (Walking Impairment Questionnaire combined) Scale: 1 to 100 (higher scores indicate better walking) · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 1 study · 62 participants | Very low |
Supervised exercise therapy vs walking advice Maximal treadmill walking distance after 3 months · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 7 studies · 624 participants | High |
Supervised exercise therapy vs walking advice Pain‐free treadmill walking distance after 3 months · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 4 studies · 508 participants | High |
Supervised exercise therapy vs walking advice Quality of life ‐ physical after 3 months (Short Form 36 physical component summary) Scale: 1 to 100 (higher scores indicate better quality of life) · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 2 studies · 296 participants | Low |
Supervised exercise therapy vs walking advice Quality of life ‐ mental after 3 months (Short Form 36 mental component summary) Scale: 1 to 100 (higher scores indicate better quality of life) · patients with intermittent claudication Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent… (2018) · Cochrane | no estimate extracted | 2 studies · 296 participants | Low |
Rutosides vs placebo (or no treatment) Occurrence of leg ulceration · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Rutosides vs an alternative venoactive remedy (hidrosmina) Improvement in PTS (6 months) · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | OR 0.18 [0.04, 0.94] | 1 study · 29 participants | Low |
Rutosides vs an alternative venoactive remedy (hidrosmina) Deterioration in PTS (6 months) · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | OR 0.19 [0.01, 4.24] | 1 study · 29 participants | Low |
Rutosides vs an alternative venoactive remedy (hidrosmina) Adverse effects · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Rutosides vs placebo (or no treatment) Improvement in PTS (8 weeks ‐ 12 months) · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | OR 1.29 [0.69, 2.41] | 2 studies · 164 participants | Low |
Rutosides vs placebo (or no treatment) Deterioration in PTS (8 weeks ‐ 12 months) · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | OR 0.61 [0.19, 1.9] | 1 study · 80 participants | Low |
Rutosides vs placebo (or no treatment) Adverse effects (8 weeks ‐ 12 months) · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Rutosides vs elastic compression stockings Occurrence of leg ulceration · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Rutosides vs elastic compression stockings Improvement in PTS (12 months) · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | OR 0.8 [0.31, 2.03] | 1 study · 80 participants | Low |
Rutosides vs elastic compression stockings Deterioration in PTS (12 months) · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | OR 0.61 [0.19, 1.9] | 1 study · 80 participants | Low |
Rutosides vs elastic compression stockings Adverse effects (12 months) · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Rutosides vs an alternative venoactive remedy (hidrosmina) Occurrence of leg ulceration · patients with PTS Rutosides for treatment of post‐thrombotic syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Prostanoids vs placebo Cardiovascular mortality · people with critical limb ischaemia Prostanoids for critical limb ischaemia (2018) · Cochrane | RR 0.81 [0.41, 1.58] | 3 studies · 1170 participants | Low |
Prostanoids vs pentoxifylline Adverse events (participants) · people with critical limb ischaemia Prostanoids for critical limb ischaemia (2018) · Cochrane | RR 0.6 [0.24, 1.47] | 1 study · 70 participants | Very low |
Prostanoids vs pentoxifylline Rest‐pain relief · people with critical limb ischaemia Prostanoids for critical limb ischaemia (2018) · Cochrane | RR 1.4 [0.72, 2.72] | 1 study · 70 participants | Very low |
Prostanoids vs pentoxifylline Ulcer healing · people with critical limb ischaemia Prostanoids for critical limb ischaemia (2018) · Cochrane | RR 1.61 [1.13, 2.3] | 1 study · 70 participants | Very low |
Prostanoids vs naftidrofuryl Cardiovascular mortality · people with critical limb ischaemia Prostanoids for critical limb ischaemia (2018) · Cochrane | no estimate extracted | NR | No studies |
Prostanoids vs naftidrofuryl Total amputations · people with critical limb ischaemia Prostanoids for critical limb ischaemia (2018) · Cochrane | RR 0.96 [0.57, 1.64] | 1 study · 29 participants | Low |
Prostanoids vs naftidrofuryl Quality of life · people with critical limb ischaemia Prostanoids for critical limb ischaemia (2018) · Cochrane | no estimate extracted | NR | No studies |
Prostanoids vs naftidrofuryl Adverse events (participants) · people with critical limb ischaemia Prostanoids for critical limb ischaemia (2018) · Cochrane | RR 3.29 [0.27, 40.19] | 2 studies · 55 participants | Low |